Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Liver International

Volumn 37, Issue 2, 2017, Pages 205-211

  Tacke, Frank ^a   Günther, Rainer ^b   Buggisch, Peter ^c   Klinker, Hartwig ^d   Schober, Andreas ^e   John, Christine ^f   Lutz, Thomas ^g   Pfeiffer Vornkahl, Heike ^h   Niederau, Claus ⁱ   Cornberg, Markus ^j   Sarrazin, Christoph ^k   Mauss, Stefan ^l  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Ifi Institute for Interdisciplinary Medicine   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e Hepatologische Praxis   (Germany)

^f Hepatologische Praxis   (Germany)

^g Infektiologikum   (Germany)

^h E factum GmbH   (Germany)

ⁱ St Josef Hospital Oberhausen   (Germany)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l Center for HIV and Hepatogastroenterology   (Germany)

more..

Author keywords

cirrhosis; fibrosis; genotype 2; HCV; real life cohort; SVR12

Indexed keywords

DACLATASVIR; HEMOGLOBIN; INTERFERON; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASCITES; CARDIOVASCULAR DISEASE; CHRONIC HEPATITIS C; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESOPHAGUS VARICES; FAINTNESS; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HISTOPATHOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; REINFECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; ADOLESCENT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; GERMANY; HEPACIVIRUS; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; REGISTER; STATISTICAL MODEL; SUSTAINED VIROLOGIC RESPONSE; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; YOUNG ADULT;

EID: 84994340595     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13206     Document Type: Article

References (29)

1. Tacke F, Kroy DC, Barreiros AP, Neumann UP. Liver transplantation in Germany. Liver Transplant. 2016;22:1136–1142.
2. Vermehren J, Schlosser B, Domke D, et al. High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28 809 patients. PLoS ONE. 2012;7:e41206.
3. Wolffram I, Petroff D, Batz O, et al. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol. 2015;62:1256–1264.
4. Bruggmann P, Berg T, Ovrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepatitis. 2014;21(Suppl 1):5–33.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
6. Heidrich B, Wiegand SB, Buggisch P, et al. Treatment of naive patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PLoS ONE. 2014;9:e108751.
7. Hofmann WP, Mauss S, Lutz T, et al. Benefit of treatment individualization in patients with chronic hepatitis C receiving peginterferon alfa-2a and ribavirin in a large noninterventional cohort study. PLoS ONE. 2015;10:e0134839.
8. European Association for Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
9. Sarrazin C, Berg T, Buggisch P, et al. S3 guideline hepatitis C addendum. Z Gastroenterol. 2015;53:320–334.
10. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
11. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
12. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.
13. Kao JH, Chien RN, Chang TT, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int. 2016;36:1101–1107.
14. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
15. Mangia A, Arleo A, Copetti M, et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int. 2016;36:971–976.
16. Zhou N, Han Z, Hartman Neumann S, et al. High sustained virologic response rates in patients infected with genotype 2 with baseline NS5A polymorphisms treated with daclatasvir-based regimens. J Hepatol. 2016;64:S407.
17. Manns MP, von Hahn T. Novel therapies for hepatitis C—one pill fits all? Nat Rev Drug Discov. 2013;12:595–610.
18. Mangia A, Arleo A, Piazzolla V, et al. Sustained virological responses (SVR) of 97% in genotype 2 (GT-2) patients with F3/4 stage of fibrosis treated with sofosbuvir (SOF) and weight-based ribavirin (RBV): a real life, single centre experience. J Hepatol. 2016;64:S246–S247.
19. Welzel TM, Nelson DR, Morelli G, et al. Safety and efficacy of sofosbuvir and ribavirin for the treatment of HCV genotype 2 and 3: results of the HCV-TARGET study. Hepatology. 2015;62:727A–728A.
20. Saez-Royuela F, Badia E. Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success? Liver Int. 2016;36:1093–1095.
21. Ahn SH, Lim YS, Lee KS, et al. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepatitis. 2016;23:358–365.
22. Liakina V, Hamid S, Tanaka J, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries—volume 3. J Viral Hepatitis. 2015;22(Suppl 4):4–20.
23. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther. 2015;42:559–573.
24. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol. 2002;76:4034–4043.
25. Raghwani J, Thomas XV, Koekkoek SM, et al. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b. J Virol. 2012;86:2212–2220.
26. De Keukeleire S, Descheemaeker P, Reynders M. Potential risk of misclassification HCV 2k/1b strains as HCV 2a/2c using VERSANT HCV Genotype 2.0 assay. Diagn Microbiol Infect Dis. 2015;82:201–202.
27. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149:1462–1470.
28. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–2607.
29. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.